Swiss Life Asset Management Ltd Grows Position in Insmed, Inc. $INSM

Swiss Life Asset Management Ltd grew its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 60.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,004 shares of the biopharmaceutical company’s stock after acquiring an additional 5,288 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Insmed were worth $2,437,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. CIBC Private Wealth Group LLC increased its position in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares in the last quarter. Kingsview Wealth Management LLC increased its position in Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 60 shares in the last quarter. Choreo LLC grew its position in shares of Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 65 shares during the period. ORG Partners LLC grew its position in shares of Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 74 shares during the period. Finally, Everpar Advisors LLC grew its position in shares of Insmed by 8.3% in the fourth quarter. Everpar Advisors LLC now owns 1,573 shares of the biopharmaceutical company’s stock valued at $274,000 after purchasing an additional 120 shares during the period.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent analyst reports. Leerink Partners lifted their price objective on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research report on Tuesday, March 24th. Mizuho lifted their price objective on Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. Roth Mkm reaffirmed a “buy” rating and issued a $212.00 price objective on shares of Insmed in a research report on Friday, April 17th. Jefferies Financial Group initiated coverage on Insmed in a research report on Monday, March 16th. They issued a “buy” rating and a $228.00 price objective for the company. Finally, Wells Fargo & Company lowered their price objective on Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Insmed has an average rating of “Moderate Buy” and an average price target of $210.95.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the sale, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,361,604.45. The trade was a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the sale, the insider directly owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 161,193 shares of company stock valued at $25,462,012. Company insiders own 2.10% of the company’s stock.

Insmed Price Performance

INSM stock opened at $115.62 on Friday. The stock has a 50-day moving average price of $142.14 and a two-hundred day moving average price of $163.64. Insmed, Inc. has a 12-month low of $64.85 and a 12-month high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The company has a market cap of $25.06 billion, a PE ratio of -20.11 and a beta of 0.89.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the previous year, the business earned ($1.42) earnings per share. The firm’s quarterly revenue was up 229.7% compared to the same quarter last year. As a group, research analysts predict that Insmed, Inc. will post -2.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.